Business Wire

Merck KGaA, Darmstadt, Germany Selects Cambridge Semantics as Enterprise Data Fabric Provider

16.7.2020 15:00:00 EEST | Business Wire | Press release

Share

Cambridge Semantics, the leading provider of modern, graph-driven data integration for the enterprise data fabric, today announced that Merck KGaA, Darmstadt, Germany and its US-based biopharmaceutical business EMD Serono, have selected Cambridge Semantics as its data fabric provider.

Through this multi-year agreement, Cambridge Semantics will help Merck KGaA, Darmstadt, Germany establish an enterprise data fabric to support multiple data management initiatives. Cambridge Semantics’ Anzo® platform will enable Merck KGaA, Darmstadt, Germany to deliver on immediate data-driven requirements, including regulatory compliance with Identification of Medicinal Products (IDMP), while establishing a future-proof data strategy by driving further value from data and analytics.

“New regulatory requirements necessitate innovative approaches to data management,” said Jörg Werner, Associate Director Regulatory Data Governance at Merck KGaA, Darmstadt, Germany. “We selected Cambridge Semantics over other software vendors because Anzo’s underlying technology, which is based on semantics graph data models, aligns well with our data strategy to integrate and access information across research and development.”

Cambridge Semantics and Merck KGaA, Darmstadt, Germany delivered the first production solution in December 2019 focused on harmonizing and standardizing terminologies for regulatory compliance. The teams are now partnering to expand the regulatory data fabric with data from several legacy systems to provide unprecedented and comprehensive access to regularly data objects and accelerate its strategic Veeva implementation.

Cambridge Semantics’ Anzo provides a modern, graph-driven data integration platform to connect and bring meaning to all enterprise data and enable virtually anyone in an organization – from skilled data scientists to novice business users – to develop analytics-ready data sets that combine any data from any system across the enterprise. Anzo drives digital transformation and enables deep business insights when an organization’s data is highly distributed, vastly siloed, complex and when users want answers to unanticipated questions at scale and speed.

Moritz Kloft, IT Product Manager at Merck KGaA, Darmstadt, Germany added, “While we had multiple platform choices, including several based on semantics and ontology, only Cambridge Semantics has the technology, team and vision to deliver an enterprise-scale platform to support our data-driven research and development roadmap.”

“The pharmaceutical industry faces some of the most complex, critical and broad data challenges and requirements affecting business today, and it’s an industry in which having the right data can save lives,” said Chuck Pieper, Chairman and Chief Executive Officer at Cambridge Semantics. “We are incredibly proud that Merck KGaA, Darmstadt, Germany has selected Cambridge Semantics as their data management partner. We are confident that the work we do together will be transformative in building a rich data fabric and gathering new insights that Merck KGaA, Darmstadt, Germany can use for decision-making across R&D.”

Ben Szekely, Senior Vice President of Field Operations at Cambridge Semantics added, “The scale and rich history of innovation in technology R&D of Merck KGaA, Darmstadt, Germany offers the limitless potential to realize and expand our vision for the enterprise data fabric. We look forward to advancing our product roadmap and Europe-based service offerings in support of data integration and analytics initiatives of Merck KGaA, Darmstadt, Germany.”

About Cambridge Semantics

Cambridge Semantics Inc. is a modern, graph-driven data integration and analytics software company that enables seamless access to all enterprise data. Cambridge Semantics was recently recognized as a leader in Forrester Research’s Enterprise Data Fabric Wave.

The company delivers products and solutions that enable IT departments and business users across Life Sciences, Healthcare, Financial Services, Government, Manufacturing, and other industries to accelerate data delivery and to provide meaningful insights across the organization at speed and scale.

Cambridge Semantics is based in Boston, Massachusetts.

For more information visit www.cambridgesemantics.com or follow us on Facebook, LinkedIn, and Twitter: @CamSemantics.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.

The company holds the rights to the name and trademark “Merck” internationally except for the United States and Canada, where it operates in the biopharma market as EMD Serono, in life science as MilliporeSigma, and in the specialty chemicals and high/tech materials business area as EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lora Wilson / Valerie Christopherson
Global Results Communications for Cambridge Semantics
cambridge@globalresultspr.com
+1 (949) 608-0276

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Morinaga Milk Achieves Self-Affirmed GRAS Status for LAC-Living+™, Expanding U.S. Opportunities for Its Postbiotic Ingredient7.7.2026 05:00:00 EEST | Press release

Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy and functional ingredient company, today announced that it has achieved self-affirmed GRAS (Generally Recognized As Safe) status in the United States for LAC-Living+™ (L. helveticus MCC1848), its proprietary postbiotic ingredient. This milestone expands the commercial availability of LAC-Living+ in the U.S. market and enables its use in dietary supplements, functional foods, and beverages, supporting the development of products designed to address growing consumer demand for health and well-being solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706806943/en/ Growing Interest in Postbiotics and Mental Well-Being Consumer interest in proactive health management has expanded significantly in recent years, alongside increasing awareness of the connection between the gut and the brain, commonly referred to as the gut–brain axis. As a result, the g

Access Advance Welcomes New Licensors to the Video Distribution Patent Pool7.7.2026 03:00:00 EEST | Press release

Access Advance LLC today announced that Sharp, M&K Holdings, Tagivan and 9 other patent owners who own substantial video codec patent portfolios that cover the core technologies behind video decoding, processing, and streaming media delivery, have joined the Video Distribution Patent Pool (VDP Pool) in the first half of 2026. "The addition of all of these new Licensors’ patent portfolios is a real win for both the VDP Pool and our many existing and future Licensees,” said Peter Moller, CEO of Access Advance. “These companies have broad and deep patent portfolios and further enhance the program’s market leading position in resolving the licensing issues around the use of modern video codecs across all the diverse business models of internet video streaming.” The following patent holders have joined the VDP Pool as Licensors in the first half of 2026: Digital Insights Inc. Hanbat National University Industry-Academic Cooperation Foundation Hanwha Vision Co., Ltd. Industry-Academy Coopera

Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 02:00:00 EEST | Press release

Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry,

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 23:04:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately $8.8 billion net of estimated cash acquired. The transaction was unanimously approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706876183/en/ Crinetics’ marketed medicine, PALSONIFY® (paltusotine), received approval from the U.S. Food and Drug Administration (FDA) in September 2025. PALSONIFY was recently approved by the European Medicines Agency (EMA) a

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 21:30:00 EEST | Press release

The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stage name of Simone Privitera, an Italian multi-platinum DJ and producer who integrates artificial intelligence tools into a musical practice rooted in the contemporary electronic scene. With a career that has seen him collaborate wit

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye